Multiple tumor cell surface ligands and immune receptors

The term "Multiple tumor cell surface ligands and immune receptors" refers to a heterogeneous group of proteins found on the surface of cancer cells and infiltrating immune cells that regulate the anti-tumor immune response (Pardoll, 2012, Nature Reviews Cancer). This group includes immune checkpoint proteins such as Programmed Cell Death 1 (PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), as well as various tumor-associated antigens (TAAs) like HER2 or CD19 (Abbas et al., 2014, Cellular and Molecular Immunology). These molecules play critical roles in biological functions such as immune evasion, signal transduction, and cell survival within the tumor microenvironment. Tumors often upregulate inhibitory ligands to suppress T-cell activity, while immune receptors serve as the corresponding "brakes" or "accelerators" for the immune system. Therapeutic intervention typically involves monoclonal antibodies or cell-based therapies designed to either block inhibitory signaling pathways or activate cytotoxic immune responses against cells expressing specific surface ligands (NCI, 2023, Immune Checkpoint Inhibitors). Examples of drugs targeting these entities include checkpoint inhibitors like pembrolizumab and engineered therapies like CAR-T cells. Because this designation encompasses a wide array of distinct molecular entities rather than a single protein, it represents a therapeutic landscape focused on modulating the complex interactions within the tumor microenvironment.

Other names

Tumor-associated antigensImmune checkpoint moleculesTumor-specific antigensCell surface immune regulators

Modulation of immune cell activity through the binding of various cell surface receptors and ligands to either block inhibitory signals or enhance stimulatory signals.